Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
NVCT
#3038
Nuvectis Pharma, Inc. Common Stock
8.8
6
-0.78%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
-0.78%
Monthly Change
+0.68%
6 month change
+32.24%
Year Change
+27.85%
Previous Close
8.9
3
Open
8.8
6
Bid
Ask
Low
8.8
6
High
8.8
6
Volume
17
Markets
US Stock Market
Healthcare
NVCT
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
2022
2023
2024
2025
TTM
Dividends per share
0
0
0
0
—
Dividend yield %
0
0
0
0
—
Payout ratio %
0
0
0
0
—
News
Nuvectis initiates phase 1b trial combining NXP900 with osimertinib
Nuvectis Pharma stock rating reiterated at Buy by H.C. Wainwright
H.C. Wainwright reiterates Buy rating on Nuvectis Pharma stock at $10 target
Nuvectis Pharma adds former Intra-Cellular exec to board of directors
Nuvectis initiates phase 1b program for cancer drug NXP900
Nuvectis (NVCT) Q2 Loss Widens 43%
Nuvectis Pharma stock price target lowered to $10 at H.C. Wainwright
Nuvectis halts NXP800 development for ovarian cancer, shifts focus
Nuvectis reports positive drug interaction study for cancer drug NXP900
Friday’s Insider Activity: Top Buys and Sells in US Stocks
Nuvectis Pharma: Still Interesting, But Still Too Risky To Jump In
Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference